Biotech Companies Surge to Public Markets in 2026
Biotech firms completed 27 reverse mergers in the first nine months of 2026, leveraging PIPE financing to go public.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust that increased private equity investment in public biotech firms benefits retail investors?
Biotech firms completed 27 reverse mergers worth $7.5 billion through September 2026 as traditional funding sources became increasingly unavailable. This total marks a notable increase from the 12 reverse mergers recorded throughout 2025.
Why it matters
Companies are increasingly turning to reverse mergers via Nasdaq listings to bypass challenging traditional venture capital environments. This shift has been bolstered by a widespread reliance on PIPE financing to ensure liquidity.
J.P. Morgan tracked 27 reverse mergers in 2026, with 19 of those deals utilizing PIPE financing to raise capital. Notable transactions include Korsana Biosciences, which raised $380 million, while Velaris Therapeutics and Mentari Therapeutics raised $350 million and $200 million, respectively.
The players
J.P. Morgan
This global financial services firm provides investment banking and asset management services and is responsible for tracking major biotech market trends.
Korsana Biosciences
This company is a biotechnology firm that secured $380 million in capital through a reverse merger to gain entry into the public markets.
Nasdaq
This American stock exchange serves as the primary public market venue for the majority of listed biotechnology companies.
Velaris Therapeutics
This biotechnology entity utilized the reverse merger pathway to raise $350 million in funding during the 2026 period.
Mentari Therapeutics
This firm successfully raised $200 million through a reverse merger transaction to facilitate its entry into the public sector.
The details
Companies are accessing public markets by acquiring existing Nasdaq listings, a process that enables them to raise capital when traditional biotech funding becomes unavailable. PIPE financing, which involves selling shares directly to institutional investors, was used in 19 of the 27 reverse mergers recorded during the first three quarters of 2026.
Timeline
In 2021, 34 reverse mergers occurred in the biotech sector.
During 2025, firms completed 12 reverse mergers worth $9.8 billion.
Biopharma venture funding reached $9.9 billion in Q2 2026.
Biopharma venture funding totaled $6.7 billion in Q3 2026.
Total venture investment for 2026 is estimated to hit $33 billion.
The Tech Race
The current rise in reverse mergers marks a pivot for the industry as it moves away from traditional venture funding models that dominated previous years. This trend positions these biotech firms to maintain liquidity by accessing public markets via the 2021 biotech reverse merger cycle strategy.
Investors and market participants should monitor these reverse mergers as they indicate shifts in how biotech companies stabilize their finances for long-term operations. Increased public listing activity may influence overall industry stability and the availability of new medical innovations funded by these capital infusions.
The takeaway
The surge in reverse mergers highlights a strategic shift toward alternative financing as companies seek to navigate cooling venture capital environments. Stakeholders should observe whether this reliance on PIPE financing provides sustainable support for long-term research and development objectives.
Further reading
For more information on market trends, visit the Biotech section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Do you trust that increased private equity investment in public biotech firms benefits retail investors?
